Craft

Eloxx Pharmaceuticals

Stock Price

$0

2024-10-29

Market Capitalization

$629

2024-10-29

Eloxx Pharmaceuticals Summary

Company Summary

Overview
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for rare genetic diseases. It focuses on the discovery, development, and commercialization of compounds for the treatment of Alport syndrome and ADPKD caused by nonsense mutations.
Type
Public
Status
Active
Founded
1999
Website
https://www.eloxxpharma.com/
Cybersecurity rating
ESG rating
30-39 out of 100|View all ESG data
Sectors

Key People

  • Sumit Aggarwal

    Sumit Aggarwal, President and Chief Executive Officer

  • Ali Hariri

    Ali Hariri, Chief Medical Officer

  • Daniel Geffken

    Daniel Geffken, Interim Chief Financial Officer

  • Tomer Kariv, Chairman

    LocationsView all

    2 locations detected

    • Waltham, MA

      United States

      950 Winter St

    • Rehovot, Center District

      Israel

      10 Prof. Menachem Plaut Street

    Eloxx Pharmaceuticals Financials

    Summary Financials

    Net income (Q1, 2026)
    ($3.8M)
    Cash (Q1, 2026)
    $6.4M
    EBIT (Q1, 2026)
    ($3.8M)

    Footer menu